Bhavananda Reddy, MD
Interventional Cardiology · Farmington, UTNPI 1326130758
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Boston Scientific at 30.3% of the total. Reporting peaked in 2019 at $6,708 and has fallen 95.8% since, to $279 in 2025.
Across 219 payments — averaging $72.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$3K
- Inari Medical, Inc.$2K
- Abbott$1K
- Philips North America LLC$1K
- Shockwave Medical, Inc$1K
- plus $2K from 14 others
Across 8 payments — averaging $1589.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$13K
What the payments were for
- Consulting fees$3,00019%
- Travel & lodging$6,32740%
- Food & beverage$6,46041%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 33 | $4,798 |
| Medtronic(2 entities) | 30 | $3,147 |
| Inari Medical, Inc. | 8 | $1,842 |
| Abbott | 40 | $1,393 |
| Philips North America LLC | 8 | $1,339 |
| Shockwave Medical, Inc | 48 | $1,053 |
| W. L. Gore & Associates, Inc. | 9 | $908 |
| Abiomed | 2 | $266 |
| Novartis | 11 | $250 |
| Kestra Medical Technology Services, Inc. | 5 | $211 |
| Impulse Dynamics (USA) Inc. | 2 | $205 |
| Amgen | 7 | $112 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $100 |
| Novo Nordisk | 3 | $71 |
| Cardiovascular Systems Inc. | 1 | $63 |
| Bard Peripheral Vascular, Inc. | 2 | $32 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Cook Medical LLC | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR INTERVENTION$3,000
- FLOWTRIEVER CATHETER, S$1,735
- CT THROMBECTOMY SYSTEM KIT$1,735
- ADVISA DR MRI SURESCAN$1,661
- GENERAL - THERAPIES$1,027
- IGT D Peripheral$675
- Adapta$589
- ACUSEAL Vascular Graft$498
- IGT_D Systems$452
- OPTIMIZER$324
- Impella$266
- Perclose ProGlide suture mediated closure system$254
- Supera peripheral stent system$247
- VIABAHN Endoprosthesis$158
- EXCLUDER AAA Endoprosthesis$149
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$143
How this compares
$15,854 in reported general payments places this provider in the 75th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $108,619 |
| EntrestoSacubitril/Valsartan | 91 | $75,839 |
| XareltoRivaroxaban | 38 | $33,206 |
| Repatha SureclickEvolocumab | 17 | $21,430 |
| BrilintaTicagrelor | 12 | $8,788 |
| FarxigaDapagliflozin Propanediol | 13 | $7,858 |
| ClopidogrelClopidogrel Bisulfate | 303 | $2,398 |
| Rosuvastatin Calcium | 323 | $2,396 |
| Carvedilol | 297 | $1,881 |
| Prasugrel Hcl | 25 | $1,710 |
| Flecainide Acetate | 47 | $1,651 |
| Metoprolol Succinate | 177 | $1,458 |
| Lisinopril | 200 | $1,154 |
| Atorvastatin Calcium | 118 | $1,010 |
| Losartan Potassium | 114 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $250 | $75,83991 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 interventional cardiology providers in Utah.
Other interventional cardiology in Farmington
- Vamsee YagantiSalt Lake City$390K
- Blake GardnerSt George$267K
- Anwar TandarSalt Lake City$131K
- Sanjeev TrehanOgden$95K
- Stavros DrakosSalt Lake City$79K
- Tareq HarbOgden$27K
- Frederick WeltSalt Lake City$26K
- Jared CrisafiSt George$24K
- Scott HackingSalt Lake City$22K
- Eric LindleySalt Lake City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.